Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF

Docherty, K. F. , Vaduganathan, M., Solomon, S. D. and McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8(10), pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)

[img] Text
222798.pdf - Accepted Version
Restricted to Repository staff only until 28 September 2021.



Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to reduce the risk of cardiovascular death or heart failure hospitalization and improve symptoms among patients with chronic heart failure with reduced ejection fraction compared to enalapril, the gold standard angiotensin-converting enzyme inhibitor. In the 5 years since the publication of the results of PARADIGM-HF, further insight has been gained into integrating a neprilysin inhibitor into a comprehensive multidrug regimen, including a renin-angiotensin aldosterone system (RAS) blocker. This paper reviews the current understanding of the effects of sacubitril/valsartan and highlights expected developments over the next 5 years, including potential new indications for use. Additionally, a practical, evidence-based approach is provided to the clinical integration of sacubitril/valsartan among patients with heart failure with reduced ejection fraction.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Docherty, Dr Kieran and McMurray, Professor John
Authors: Docherty, K. F., Vaduganathan, M., Solomon, S. D., and McMurray, J. J.V.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:JACC: Heart Failure
Publisher:Elsevier on behalf of the American College of Cardiology Foundation
ISSN (Online):2213-1787
Published Online:28 September 2020

University Staff: Request a correction | Enlighten Editors: Update this record